Sponsors for KIN Research:


NIH's Stem Cell Task Force

"They are really supporting this guy!", says Chairman Natto.



Before the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies

Committee on Appropriations

United States Senate



Alternative Methods of Obtaining Embryonic Stem Cells

Statement of 

James F. Battey, M.D., Ph.D.


National Institute on Deafness and Other Communication Disorders, and Chair, NIH Stem Cell Task Force

U.S. Department of Health and Human Services




                                                For Release on Delivery

Expected at 9:30 a.m.

                        Tuesday, July 12, 2005


Mr. Chairman, Senator Harkin, and Members of the Subcommittee, I am pleased to appear before you today to testify about stem cell research.  Human embryonic stem cells (hESC) have proven to be an important tool for advancing our knowledge about cell specialization, and have great potential to be medically valuable.  However, using established methods, these unique cells cannot be obtained without destroying human embryos.  There have been recent announcements about alternative ways to establish human pluripotent stem cell lines that claim to avoid the contentious issues of creating, destroying or harming human embryos.  This past May, the President’s Council on Bioethics published a white paper on “Alternative Sources of Human Pluripotent Stem Cells.”  I am focusing my testimony on analysis of the methods highlighted in this report. 


Pluripotent Stem Cells from Dead Embryos

Drs. Donald Landry and Howard Zucker at Columbia University College of Physicians and Surgeons noted that during the human in vitro fertilization (IVF) process, there are numerous embryos that fail to continue to divide, and are therefore judged to be unsuitable for implantation.  These non-dividing entities are deemed to be “dead,” and they propose that harvesting cells from these embryos for the purpose of creating a hESC line is no different than organ donation by a person judged to be “brain dead.”  They argue that this approach is morally acceptable.


From a scientific perspective, there is no published study showing that it is possible to generate an embryonic stem cell line from a non-dividing, “dead” embryo in rodents, non-human primates or humans.  If stem cell lines could be derived from such embryos, the resulting cell line would have to be carefully checked for karyotypic (genetic) abnormalities or other defects, which may have been the underlying cause of the embryo’s lack of development.  This research will require that clear criteria be established to determine when a “non-dividing embryo” is dead.


Finally, the Dickey Amendment to the Department of Health and Human Services (DHHS) appropriations act prohibits the use of funds appropriated to DHHS to support the creation of a human embryo for research purposes or research in which a human embryo is destroyed, discarded, or subjected to risk of injury or death greater than that allowed under Federal requirements for fetuses in utero.  Applicability of this prohibition would have to be analyzed before NIH could fund research on this technique using human embryos.


Pluripotent Stem Cells from Biopsied Blastomeres

This proposal, suggested by Representative Roscoe Bartlett (R-MD), involves creating an embryonic stem cell line by using a blastomere cell from an embryo.  When performing pre-implantation genetic diagnosis (PGD), a single blastomere cell is removed from an 8-cell stage embryo (approximately Day 3 in embryo development where all cells are assumed to be totipotent) for genetic analysis, and the remaining seven cells constituting the embryo are used for reproductive purposes through the standard IVF procedure.  The proponents of this proposal suggest that this is proof of principle that removal of a single cell does not frequently damage the remaining embryo.  Using this premise, this proposal argues that a single cell, or several cells, might be removed from an embryo at the 8-cell stage at the same time the embryo is undergoing PGD and these additional cell(s) could be used for the purpose of creating a hESC line.  The proposal further argues that if one limits this approach to embryos undergoing PGD, one is: 1) not compromising any embryos that are not already being compromised for PGD; and 2) assured the embryos being used were created only for reproductive purposes.


From a scientific perspective, NIH is not aware of any published scientific data that confirms the establishment of hESC lines from a single cell removed from an 8-cell stage embryo.  We are aware of the published research of Dr. Yury Verlinsky at the Reproductive Genetics Institute in Chicago that showed that a hESC line can be derived by culturing a human morula-staged embryo (Reproductive BioMedicine Online, 2004 Vol. 9, No. 6, 623-629, Verlinsky, Strelchenko, et al).  It is also worth noting, however, that in these experiments, the entire morula was plated and used to derive the hESC lines.  The human morula is generally composed of 10-30 cells and is the stage (Day 4) that immediately precedes the formation of the blastocyst (Day 5).  It is not known whether a hESC line can be created from a single cell or a few cells because these cells appear to require close contact with surrounding cells for survival and for maintenance of the pluripotent state.  Even with the hESCs derived from the inner cell mass of the human blastocyst, the odds of starting a hESC line from a single cell are poor, perhaps one in 20 tries.  Thus, the odds of being able to start with a single cell from an 8-cell or morula stage embryo are likely to be challenging. 


NIH believes that such experiments might be pursued in animals, including non-human primates.  Experiments in animal model systems could be conducted to determine whether it is possible to derive hESCs from a single cell of the 8-cell or morula stage embryo.  To date, NIH is aware of only two published reports where scientists developed mouse stem cell lines from individual blastomeres.  NIH also does not know whether these experiments have been tried and failed in other animals and/or humans and, therefore, have not been reported in the literature.  NIH explored whether there have been any attempts to use single cells from the 8-cell or morula stage of an animal embryo to start embryonic stem cell lines by consulting with scientists that are currently conducting related embryo research.  From these discussions, these scientists believe it is worth attempting experiments using a single cell from an early stage embryo or cells from a morula of a non-human primate to establish an embryonic stem cell line.  If this approach is successful, the resulting stem cell lines would, of course, have to be validated for genetic stability, pluripotency, and unlimited self-renewal — all cardinal features of embryonic stem cell lines generated from blastocysts by culturing the inner cell mass.


NIH concludes that the possibility of establishing a hESC line from an 8-cell or morula stage embryo can only be determined with additional research.  NIH would welcome the receipt of investigator-initiated grant applications on this topic using animal embryos.  As with all grant applications, such proposals would be judged for scientific merit by peer review and then will be awarded research funds if sufficient funds are available.  


Live births resulting from human embryos that undergo PGD and are subsequently implanted seem to suggest that this procedure does not harm the embryo; however, there are some reports that some embryos do not survive this procedure.  In addition, long-term studies are needed to determine whether this procedure produces subtle injury to children born following PGD.  This experiment in human embryos at either the morula or the blastocyst stage would require evaluations of not only normal birth but also unknown long-term risks to the person even into adulthood. 


Moreover, there are a number of questions to be resolved with regard to the nature of the cells removed from the 8-cell stage embryo.  If the cells removed at this stage are totipotent (and most scientists would agree they are), then it might be argued that these cells are themselves embryos, i.e., having the potential to undertake all of the life functions of the adult.  It is possible, however, that one could put these cells in an environment in which they will not continue to develop and, under these conditions, they would no longer be embryos. 


As with the Landry-Zucker proposal, applicability of the Dickey Amendment would have to be analyzed before NIH could fund research on human embryos.


Pluripotent Stem Cells from Biological Artifacts

Dr. William Hurlbut at Stanford University asserts that it may be possible to do the following:  (1) genetically modify a somatic cell in culture, either reversibly or irreversibly inactivating a gene essential for normal trophoblast function/development (which is required for embryo implantation and development of the placenta); (2) use this genetically modified somatic cell as the source of a nucleus and genome for somatic cell nuclear transfer (SCNT) into a human oocyte.  Dr. Hurlbut refers to this method as Altered Nuclear Transfer (ANT); (3) allow this oocyte to proceed to develop into a blastocyst; and (4) attempt to generate a hESC line from the inner cell mass of the blastocyst.  Dr. Hurlbut argues that since the entity generated by SCNT had no capacity to develop a trophectoderm (the embryonic cells which becomes the placenta and umbilical cord), it never had the capacity to develop into a fetus and ultimately a child; it is, therefore, not a human embryo.  Dr. Hurlbut asserts that since this entity is not a human embryo, and its destruction at the blastocyst stage to generate a hESC line is morally acceptable.  His opinion is currently under debate. 


From a scientific perspective, Dr. Janet Rossant at Mount Sinai Hospital in Toronto has identified a gene essential for normal trophoblast development/function in a mouse model system.  However, no one has demonstrated that it is possible to execute the sequence of steps proposed by Dr. Hurlbut and obtain a pluripotent, genetically stable stem cell line.  Embryonic stem cell derivations would need to undergo pilot experiments, first in rodents and then in non-human primates, to prove that this approach has merit and is technically feasible.  If created, the stem cell lines would, of course, have to be validated as authentic, with all the properties associated with self-renewing, pluripotent embryonic stem cell lines.


Dr. Hurlbut’s proposed approach to deriving hESCs is dependent upon the widespread acceptance of his assertion that the genetically modified entity created using his procedure is not, in fact, a human embryo.


There are no limitations on any pilot studies performed in rodents or non-human primates.  Limits of Federal funding of research for any extension of this approach to humans would require an analysis of the applicability of the Dickey Amendment.



Pluripotent Stem Cells by Reprogramming Somatic Cells

This proposal involves reprogramming human somatic cells, perhaps with the aid of special cytoplasmic factors obtained from oocytes (or from pluripotent embryonic stem cells), so as to “dedifferentiate” them back into pluripotent stem cells.  Crucial to this approach is discovering a way to reverse cell differentiation all the way back to pluripotency, but not further back to totipotency.  


From a scientific perspective, it may be possible at some time in the future to culture populations of somatic cells in the laboratory and reverse their differentiating process, enabling them to become pluripotent.  Scientists may also identify the molecules in cells such as embryonic stem cells that are responsible for maintaining cells in a pluripotent state and use these factors to dedifferentiate somatic cells.  This proposal would raise ethical issues if the dedifferentiation process were to proceed too far and create a totipotent cell (a cloned human zygote).  Research conducted with somatic cells can be conducted with appropriated funds since no human embryos are involved, unless the dedifferentiation process proceeds too far and results in the creation of a cell equivalent to a zygote.



Although some of these approaches may address interesting scientific questions and may even lead to new ways to derive stem cells, science works best when all available avenues can be pursued simultaneously.


NIH places a high priority on support for research using embryonic and non-embryonic stem cells that will also be useful for basic, translational, and clinical studies.  The NIH is very grateful for your continued support.  I look forward to working with you to advance this and all fields of biomedical research.  I will be happy to try to answer any questions that you and the Subcommittee might have. 


Disclaimer of Warranty and Limitation of Liability
The information, products and services on this web site or letter are provided on an "AS IS," "WHERE IS" and "WHERE AVAILABLE" basis.  The KIN Consortium does not warrant the information or services provided herein or your use of this web site generally, either expressly or impliedly, for any particular purpose and expressly disclaims any implied warranties, including but not limited to, warranties of title, non-infringement, merchantability or fitness for a particular purpose. The KIN Consortium  will not be responsible for any loss or damage that could result from interception by third parties of any information or services made available to you via this web site. Although the information provided to you on this web site is obtained or compiled from sources we believe to be reliable, The KIN Consortium  cannot and does not guarantee the accuracy, validity, timeliness or completeness of any information or data made available to you for any particular purpose. Neither The KIN Consortium , nor any of its affiliates, directors, officers or employees, nor any third party vendor, will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or interruption of this web site, or resulting from the act or omission of any other party involved in making this web site, the data contained herein or the products or services offered on this web site available to you, or from any other cause relating to your access to, inability to access, or use of the web site or these materials, whether or not the circumstances giving rise to such cause may have been within the control of The KIN Consortium  or of any vendor providing software or services. In no event will The KIN Consortium  or any such parties be liable to you, whether in contract or tort, for any direct, special, indirect, consequential or incidental damages or any other damages of any kind even if The KIN Consortium  or any other such party has been advised of the possibility thereof. This limitation on liability includes, but is not limited to, the transmission of any viruses which may infect a user's equipment, failure of mechanical or electronic equipment or communication lines, telephone or other interconnect problems (e.g., you cannot access your internet service provider), unauthorized access, theft, operator errors, strikes or other labor problems. The KIN Consortium  cannot and does not guarantee continuous, uninterrupted or secure access to the web site.

Proprietary Rights
All right, title and interest in this web site and any content contained herein is the exclusive property of The KIN Consortium , except as otherwise stated. Unless otherwise specified, this web site is for your personal and non-commercial use only and you may print, copy and download any information or portion of this web site for your personal use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, frame, create derivative works from, transfer, or otherwise use in any other way for commercial or public purposes in whole or in part any information, software, products or services obtained from this web site, except for the purposes expressly provided herein, without The KIN Consortium's prior written approval. If you copy or download any information or software from this web site, you agree that you will not remove or obscure any copyright or other notices or legends contained in any such information.

The KIN Consortium and other trademarks and service marks referenced herein are trademarks and service marks of The KIN Consortium . The names of other companies and third-party products or services mentioned herein may be the trademarks or service marks of their respective owners. You are prohibited from using any marks for any purpose including, but not limited to use as metatags on other pages or sites on the World Wide Web without the written permission of The KIN Consortium  or such third party, which may own the marks.

Pursuant to Section 512(c)(2) of the Copyright Act, The KIN Consortium  designates the following agent to receive notifications of claimed infringement: Khalid I Natto, The KIN Consortium , Email:
kalnatto2000@yahoo.com Website: http://khalidnatto.tripod.com

Feedback, subscriptions, ideas? Email: kalnatto2000@yahoo.com